Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics

Tenax Therapeutics, Inc. (TENX)

Today's Latest Price: $1.05 USD

0.02 (1.94%)

Updated Dec 2 4:00pm

Add TENX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TENX Stock Price Chart Interactive Chart >

Price chart for TENX

TENX Price/Volume Stats

Current price $1.05 52-week high $2.68
Prev. close $1.03 52-week low $0.25
Day low $1.01 Volume 90,968
Day high $1.06 Avg. volume 496,564
50-day MA $1.17 Dividend yield N/A
200-day MA $1.09 Market Cap 13.25M

Tenax Therapeutics, Inc. (TENX) Company Bio

Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.

TENX Latest News Stream

Event/Time News Detail
Loading, please wait...

TENX Latest Social Stream

Loading social stream, please wait...

View Full TENX Social Stream

Latest TENX News From Around the Web

Below are the latest news stories about Tenax Therapeutics Inc that investors may wish to consider to help them evaluate TENX as an investment opportunity.

Tenax Therapeutics EPS misses by $0.09

Tenax Therapeutics (TENX): Q2 GAAP EPS of -$0.23 misses by $0.09.Cash, cash equivalents and marketable securities of $4.6M.Press Release...

Seeking Alpha | August 17, 2020

Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), today reported financial results for the second quarter 2020 and provided a business update.

Business Wire | August 17, 2020

Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD

MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), announced the appointment of Steven Boyd and Keith Maher, M.D. to the Company’s Board of Directors.

Business Wire | July 20, 2020

Tenax Therapeutics launches $8M direct offering

Tenax Therapeutics (TENX) inks agreement with institutional investor for the issuance and sale of 2,523,611 common shares at a purchase price of $1.0278/share and pre-funded warrants to purchase up to 652,313 shares of common stock, at $1.0277/per warrant, in a registered direct offering priced at-the-market.Concurrently in a private placement, the company will...

Seeking Alpha | July 7, 2020

Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules

Tenax Therapeutics, Inc. (Nasdaq: TENX) Announces $8MM Registered Direct and PIPE Offering with single healthcare-focused institutional investor

Yahoo | July 6, 2020

Read More 'TENX' Stories Here

TENX Price Returns

1-mo 28.08%
3-mo -24.46%
6-mo -21.05%
1-year -16.00%
3-year -86.88%
5-year -98.36%
YTD -25.53%
2019 16.53%
2018 -87.65%
2017 -74.87%
2016 -40.55%
2015 -14.58%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7532 seconds.